Zai Lab
Zai Lab is a biopharmaceutical company based in Shanghai, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2014, the company has built a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Zai Lab also develops several investigational therapies, such as REGN1979 for lymphomas, Margetuximab for HER2-positive cancers, and Omadacycline for bacterial infections. The company has established partnerships with leading global biopharmaceutical firms to enhance its research and development capabilities and expand its market reach. Zai Lab operates in an increasingly favorable clinical and regulatory environment in China, aiming to deliver transformative medicines to patients both locally and internationally while leveraging its in-house manufacturing capabilities to support drug production.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.